Business Description
Kiora Pharmaceuticals Inc
NAICS : 325413
SIC : 2835
Compare
Compare
Traded in other countries / regions
7EY0.GermanyKPRX.USADescription
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The products pipeline of the company includes KIO-101, KIO-201, KIO-301, and KIO-102.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 35.31 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Beneish M-Score | -3.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -100 | |||||
| 3-Year EBITDA Growth Rate | 31.7 | |||||
| 3-Year EPS without NRI Growth Rate | 32.1 | |||||
| 3-Year FCF Growth Rate | 38.2 | |||||
| 3-Year Book Growth Rate | -27.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.91 | |||||
| 9-Day RSI | 26.79 | |||||
| 14-Day RSI | 30.36 | |||||
| 6-1 Month Momentum % | -67.45 | |||||
| 12-1 Month Momentum % | -88.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | |||||
| Quick Ratio | 2.21 | |||||
| Cash Ratio | 1.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -138.21 | |||||
| ROA % | -89.57 | |||||
| ROIC % | -84.43 | |||||
| ROC (Joel Greenblatt) % | -5803.02 | |||||
| ROCE % | -88.79 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.36 | |||||
| EV-to-EBIT | 0.04 | |||||
| EV-to-EBITDA | 0.04 | |||||
| EV-to-FCF | 0.05 | |||||
| Earnings Yield (Greenblatt) % | 2500 |